Isis in Medical News
Navigation Links
Isis in Medical News
Webcast Alert: Isis Pharmaceuticals' Second Quarter 2009 Financial Results Conference Call
CARLSBAD, Calif., July 23 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announces the following webcast: What: Isis Pharmaceuticals' Second Quarter 2009 Financial Results When: Thursday, August 6, 2009 at 8:30 a.m. ET / 5:30 a.m. PT ...CARLSBAD, Calif., May 19 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announces the following webcast: What: Isis Pharmaceuticals to provide a general corporate update in conjunction with the 2009 Annual Meeting of Stockholders. The co...
Webcast Alert: Isis Pharmaceuticals' Cardiovascular Program Review
NEW ORLEANS and CARLSBAD, Calif., Nov. 6 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announces the following webcast: What: Isis' cardiovascular program review of development and late-stage research candidates, including presentations ...FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen
Isis to Host Conference Call Today at 8 a.m. EDT CARLSBAD, Calif. and CAMBRIDGE, Mass., April 25 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) and Genzyme Corp. (Nasdaq: GENZ ) announced today that the FDA has provided guidance regarding approval requirements for mip...Isis Announces ISIS 333611 Granted Orphan Drug Status for Treatment of ALS
CARLSBAD, Calif., Dec. 13 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug status to ISIS 333611 for the treatment of an inherited form of amyotrophic lateral sclerosis (ALS), commonly...CARLSBAD, Calif., Oct. 18 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) today announced that it has added a new diabetes drug targeting the sodium dependent glucose transporter type 2 (SGLT2) to its development pipeline. ISIS 388626, a generation 2.2 antisense drug that...
Isis Favorably Revises Financial Guidance and Introduces Mipomersen as Generic Name for ISIS 301012
- ISIS 301012 given generic name mipomersen sodium - Isis further reduces its 2007 net operating loss guidance to mid to high $20 million range - Isis will host a conference call this morning at 8:00 a.m. E.T. at http://www.isisph...Isis Reports That ISIS 301012 is Well Tolerated in Patients Treated for Five Or More Months
- Twelve of Sixteen FH Patients in an Ongoing Open-Label Extension Study Have Been Dosed With ISIS 301012 for Approximately Five Months or More, and Four Have Been Dosed for More Than Six Months - Isis Will Host a Conference Call on Monday, October 8, at 8:00 a.m. E.T. ...Abbott Completes Acquisition of Ibis Biosciences, a Subsidiary of Isis
CARLSBAD, Calif. and ABBOTT PARK, Ill., Jan. 6 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) and Abbott (NYSE: ABT ) announced today that Abbott has completed its purchase of Ibis Biosciences, Inc., an Isis subsidiary, for a closing purchase price of $175 million. In ad...Grassrootshealth Launches D*action Community Project to Solve Vitamin D Deficiency Crisis
Serving as a model for public health action on vitamin D, GrassrootsHealth, an advocacy organization has launched the D*action Community Project, a consortium of scientists, institutions and individuals committed to solving the worldwide vitamin D deficiency crisis and will hold its first event, ...Isis Pharmaceuticals to Present at Canaccord Adams' 29th Annual Global Growth Conference
...CARLSBAD, Calif., Aug. 4 /PRNewswire-FirstCall/ -- isis Pharmaceuticals, Inc. (Nasdaq: isis ), the leader in antisense therapeutics, today ann...eplay of the presentation will be available on the isis Web site within 48 hours and will be archived for ......nd, Canada Validation of LRRK2 as a drug target for treatment of Parkinson's disease using antisense technology Alejandro Lloret, PhD, isis Pharmaceuticals, Inc., Carlsbad, California Optimizing lead series of small molecule inhibitors of LRRK2 to deliver tool compounds and clini...
Vanderbilt researchers pioneer an advanced sepsis detection and management system
...dly, expensive and treatable. At the same time, isis computer scientists were investigating the issue o...gy) Science and Technology Center. When Miller and isis Director Janos Sztipanovits compared notes, they realized that isis had developed computer-modeling tools that could b...Isis Pharmaceuticals to Present at Jefferies' 3rd Annual Healthcare Conference
...ARLSBAD, Calif., June 11 /PRNewswire-FirstCall/ -- isis Pharmaceuticals, Inc. (Nasdaq: isis ), the leader in antisense therapeutics, today ann...eplay of the presentation will be available on the isis Web site within 48 hours and will be archived for ...Isis Pharmaceuticals to Present at Needham's 8th Annual Life Sciences Conference
...CARLSBAD, Calif., June 5 /PRNewswire-FirstCall/ -- isis Pharmaceuticals, Inc. (Nasdaq: isis ), the leader in antisense therapeutics, today ann...eplay of the presentation will be available on the isis Web site within 48 hours and will be archived for ...Isis Pharmaceuticals to Present at Goldman Sachs' 30th Annual Global Healthcare Conference
...CARLSBAD, Calif., June 4 /PRNewswire-FirstCall/ -- isis Pharmaceuticals, Inc. (Nasdaq: isis ), the leader in antisense therapeutics, today ann...eplay of the presentation will be available on the isis Web site within 48 hours and will be archived for ...Isis Highlights New Clinical Data on Anti-Cancer Antisense Drugs Featured at ASCO
...CARLSBAD, Calif., June 1 /PRNewswire-FirstCall/ -- isis Pharmaceuticals, Inc. (Nasdaq: isis ) announced today that Isis' collaborators present...1 and OGX-427 are antisense drugs co-discovered by isis and OncoGenex (Nasdaq: OGXI ) and...Isis Reports Strong Financial Results and Highlights for First Quarter of 2009
... CARLSBAD, Calif., May 7 /PRNewswire-FirstCall/ -- isis Pharmaceuticals, Inc. (Nasdaq: isis ) today announced its financial results for the qu...marily as a result of the $171.8 million gain that isis recognized from selling its Ibis Biosciences subsi...Isis Scientist Awarded 2009 Ebert Prize
...ARLSBAD, Calif., April 6 /PRNewswire-FirstCall/ -- isis Pharmaceuticals, Inc. (Nasdaq: isis ) announced today that Lloyd G. Tillman, Ph.D., Executive Director of Pharmaceutical Development of isis has been awarded the American Pharmacists Associat...Isis Reports Strong Financial Results and Highlights for Fiscal Year 2008
...ARLSBAD, Calif., Feb. 25 /PRNewswire-FirstCall/ -- isis Pharmaceuticals, Inc. (Nasdaq: isis ) today announced its 2008 financial results and business highlights. isis exceeded its 2008 financial guidance by ending 200...Misonix Reports Earnings and Increased Revenues for the Three and Six Months Ended December 31, 2008
...of the strengthening of the U.S. dollar against the English pound, Labcaire sales increased $795,000 in the second quarter due to shipments of our new isis endoscope cleaning system, endoscope storage cabinet and increased service revenue. In light of the challenging global economic environment, w...Isis Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
...CARLSBAD, Calif., Jan. 8 /PRNewswire-FirstCall/ -- isis Pharmaceuticals, Inc. (Nasdaq: isis ) announced that the Company will present at the 2...imited time on the Company's Web site. About isis Pharmaceuticals, Inc. ...... and Technology Facilities Council's world leading isis neutron source. Research at isis is showing exactly how the calcium is held in the ...lains that it was when the material was studied at isis that the process became clear. "Although variants...
Isis' Partners Present Clinical Data on Antisense Drugs at the American Society of Clinical Oncology
...FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: isis ) announced today that two of the Company's partne...as jointly discovered and is being co-developed by isis and OncoGenex. Lilly presented first-in-human data...h.D., Vice President of Drug Discovery Research at isis Pharmaceuticals. "The encouraging safety profiles ...Isis to Receive $4.6 Million From Alnylam
...FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: isis ) announced today that it will receive $4.6 millio... value of Isis' innovation and the leadership role isis has played in the field of nucleic acid based therapeutics. isis owns or controls more than 1,500 issued patents, t...Isis Reports Financial Results and Highlights for First Quarter of 2008
...FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: isis ) today announced its financial results for the qu...successful partnering activities. On a GAAP basis, isis recorded a 2008 loss from operations for the quart...lion in the first quarter of 2007, a 58% decrease. isis remains on track to meet its 2008 guidance for a N...Isis Reports Financial Results and Highlights for Fiscal year 2007
...FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: isis ) today announced its 2007 financial results and b...e to its strong financial performance during 2007, isis reduced its 2007 NOL guidance from the mid to high...ivities, which are not part of ongoing operations. isis has regularly reported non-GAAP measures for opera......the HealthShares(TM) Exchange-Traded Funds, today announced that effective at the opening of trading on March 10, 2008, ISIS Pharmaceuticals (Nasdaq: isis ) will replace Pharmion Corp. (Nasdaq: PHRM ) in the HealthShares(TM) Composite Index. Synta Pharmaceuticals Corp. (Nasdaq: SNTA ) will replace Phar...
Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year
...ently in phase 3 clinical trials for high-risk cardiovascular disease patients. Mipomersen, which Genzyme is in the process of licensing from isis Pharmaceuticals Inc., will strengthen an already substantial pipeline. The product will join Mozobil and alemtuzumab at the forefront of a de......FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: isis ) announced today that its majority-owned subsidia...s' homepage at http://www.isispharm.com . ABOUT isis PHARMACEUTICALS, INC. isis is exploiting its expertise in RNA to discover and...
...Phase II trials are set to begin for survivin ASO, an antisense molecule targeted at solid tumors that Lilly is developing with its partner, isis Pharmaceuticals; a second antisense molecule targeted at solid tumors, eIF-4E ASO, is also set to begin Phase II studies in 2008. The compan...
Isis and Excaliard Collaborate to Develop Antisense Drugs for Local Treatment of Fibrotic Diseases
...CINITAS, Calif., Nov. 27 /PRNewswire-FirstCall/ -- isis Pharmaceuticals, Inc. (Nasdaq: isis ) and Excaliard Pharmaceuticals, Inc. announced to...isense drugs. Excaliard made an upfront payment to isis in the form of equity and paid...... promoting employment and self-sufficiency. Working with Abt Associates on isis will be a cadre of experienced field consultants and staff from the followi...fficiency and economic well-being of low income families with children. The isis team will identify programs and populations for evaluation through a collab...
Isis Receives $1.25 Million Milestone Payment From iCo for Initiation of Phase 1 Study of iCo-007
...FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: isis ) today announced that it has received a $1.25 mil...nical trials of iCo-007, a drug licensed to iCo by isis in 2005 for the treatment of various eye diseases,...nnett, Ph.D., Senior Vice President of Research at isis Pharmaceuticals, Inc. "We are enthusiastic about t...Isis Announces HSR Approval and Closure of Its Collaboration With Ortho-McNeil, Inc.
...FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: isis ) today announced that it has received clearance u...September 13, 2007. As part of the collaboration, isis is granting to Ortho-McNeil worldwide development ...ercialization rights to two of its diabetes drugs, isis 325568 and...Isis Acquires Symphony GenIsis
... isis 301012 now under Isis' ownership in preparation fo...FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: isis ), today announced its purchase of all of the equi...Prompting this transaction, on September 13, 2007, isis announced its metabolic disease-focused collaborat...HealthShares(TM) Announces Quarterly Rebalancing of HealthShares(TM) Indexes
... Nasdaq: AXCA Isis Pharmaceuticals Nasdaq: isis Add GPC Biotech AG-Sponsored ADR Nasdaq: GPCB QLT, Inc. .../WA SGEN 606061817.2 ISIS PHARMACEUTICALS INC isis 496697278.7 HealthShares Respiratory/Pulmonary Index Company ...Molecular Therapy Holds Promise in the Treatment of Amyotrophic Lateral Sclerosis
... Researchers from the University of California, San Diego (UCSD) School of Medicine, the Center for Neurologic Study and isis Pharmaceutical Corporation have created// and tested molecular therapy in animals which they feel will assist in the treatment of amyotrophic lateral ...Other TagsdebtsuitsuitsuitoperatetrademarkconcernedOther Contentspreviapreviapityriasisfasciitisfasciitisplagueplagueplagueplagueplantarplantarplasticplasticplasticplasticplasticplasticplasticplasticplateletplateletplateletplateletplateletplatelet
(Date:12/14/2009)... the Biomedical Engineering Society (BMES) have founded a new ... ). CVET is a forum for ... treatment. The first issue of the new quarterly ... other BMES publications at Springer, Annals of Biomedical ... , Cardiovascular Engineering and Technology will present ...
(Date:12/14/2009)... of the United Nations Framework Convention on Climate ... Agency hosted the ,Bend the Trend, event on ... platform and premiere the screening of the new ... of Europe, a joint project of the European ... and ESA, is a series of short films ...
(Date:12/13/2009)... team led by Yale University researchers has used ... for the first time. Their findings, which appear ... Nature Nanotechnology , could dramatically simplify the ... other diseases. , The teamled by ... & Applied Science, and Tarek Fahmy, an associate ...
Breaking Biology News(10 mins):Biomedical Engineering Society's new journal to be published by Springer 2'Environmental Atlas of Europe' unveiled at COP15 2Scientists use nanosensors for first time to measure cancer biomarkers in blood 2WellPoints Contribution To Drug Formulary Evaluation Standards Highlighted in ISPOR Publication 50651 1WellPoints Contribution To Drug Formulary Evaluation Standards Highlighted in ISPOR Publication 50651 2WellPoints Contribution To Drug Formulary Evaluation Standards Highlighted in ISPOR Publication 50651 3Pennsylvania DEP Lehigh Valley Berks County Air Quality Partnership Urge Public Transit Use 50648 1Pennsylvania DEP Lehigh Valley Berks County Air Quality Partnership Urge Public Transit Use 50648 2American Society of Medical Doctors Established to Protect the Bond Between Physicians and Patients 3B Organizing Doctors to Oppose Government Run Hea 50645 1American Society of Medical Doctors Established to Protect the Bond Between Physicians and Patients 3B Organizing Doctors to Oppose Government Run Hea 50645 2(Date:12/15/2009)... program will train advocates to be leaders in ... developed with support from experts in online learning, ... WASHINGTON, Dec. 15 ONE ... accepting applications for the first-ever "Malaria Griots" program, ... educate participants to become leaders in the fight ...
(Date:12/15/2009)... Dec. 15 Patient ... Women Members of Congress that, "it doesn,t matter whether ... bills - without a public option - give government ... bills also fund a new social agenda by shifting ... city groups, newly arriving immigrants, and local politicians." ...
(Date:12/15/2009)... Strike Force Operations Lead to Indictment of 30 ... more than $61 Million in Fraudulent Billing to ... -- Thirty people have been charged in three ... submit more than $61 million in false Medicare ... the Medicare Fraud Strike Force, Department of Health ...
(Date:12/15/2009)... has led the fight against malaria, and I am encouraged to ... strategies for ending malaria deaths are working,” said Dr. Daniel Carucci, ... , ... Washington, D.C. (Vocus) December 15, 2009 -- "For ... the fight against malaria, and I am encouraged to see proof ...
(Date:12/15/2009)... a new employment opportunity for the unemployed or those needing additional ... in America today. , ... Orlando, FL (PRWEB) December ... collection agencies, is spreading holiday cheer and good will that is ... has created an opportunity for out of work Americans to get ...
Breaking Medicine News(10 mins):Health News:ONE and Malaria No More Launch 'Malaria Griots' 2Health News:ONE and Malaria No More Launch 'Malaria Griots' 3Health News:ONE and Malaria No More Launch 'Malaria Griots' 4Health News:Medicare Fraud Strike Force Expands Operations Into Brooklyn, N.Y.; Tampa, Fla.; and Baton Rouge, La. 2Health News:Medicare Fraud Strike Force Expands Operations Into Brooklyn, N.Y.; Tampa, Fla.; and Baton Rouge, La. 3Health News:Medicare Fraud Strike Force Expands Operations Into Brooklyn, N.Y.; Tampa, Fla.; and Baton Rouge, La. 4Health News:Medicare Fraud Strike Force Expands Operations Into Brooklyn, N.Y.; Tampa, Fla.; and Baton Rouge, La. 5Health News:Statement by Dr. Daniel Carucci, Vice President for Global Health for the United Nations Foundation, on Progress Shown in World Malaria Report 2009 2Health News:RPS Worldwide Launches Affiliate Program -- The Collection Agency That Gives Christmas Back, Rather Than Take it Away 2Health News:RPS Worldwide Launches Affiliate Program -- The Collection Agency That Gives Christmas Back, Rather Than Take it Away 3[0] ONE and Malaria No More Launch 'Malaria Griots'[1] Hear the Truth about the Health Bills[1] Medicare Fraud Strike Force Expands Operations Into Brooklyn, N.Y.; Tampa, Fla.; and Baton Rouge, La.[0] Statement by Dr. Daniel Carucci, Vice President for Global Health for the United Nations Foundation, on Progress Shown in World Malaria Report 2009[0] RPS Worldwide Launches Affiliate Program -- The Collection Agency That Gives Christmas Back, Rather Than Take it Away
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |